Celiac Disease Foundation advocacy priorities are focused to provide more information to those living with celiac disease so that they can confidently live a healthy gluten-free life, and to advance research to drive diagnosis and ultimately find a cure. The current public policy priorities include:
- The passing of HR 2003: Gluten in Medications Disclosure Act. Currently, some medications, both prescription and over the counter, include gluten in their formulas but are not required to disclose this information. The Gluten in Medications Disclosure Act would require that all medications that contain sources of gluten list that information on their label. This listing would aid consumers and physicians both in making safe, educated healthcare decisions.
- The modification of the FDA gluten-free labeling law to include enforcement of the 20 parts per million standard for food service establishments. In August 2013, the Food and Drug Administration passed a law that mandated that if a manufacturer chooses to put “gluten-free” on food packaging the item must comply with the new FDA definition of the term – less than 20 parts per million (ppm) of gluten. This ruling was a great victory to the gluten-free community that allows consumers to buy gluten-free products with confidence. The next step is to apply this same ruling and enforcement to food service establishments. This modification to the law would ensure that those with celiac disease and non-celiac gluten sensitivity could order from gluten-free menu items at restaurants in confidence.
- Recognition by the National Institutes of Health for federal research grants. Research is limited by the amount of funding provided. Federal research grants will give celiac disease researchers the funding they need to make great strides in advancing treatment, driving diagnosis, managing symptoms, and finding a cure for celiac disease.